An Open-label Study of Xeloda Plus Taxotere on Treatment Response in Patients With HER2-neu-negative, and the Addition of Herceptin for HER2-neu-positive Breast Cancer.
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2011
At a glance
- Drugs Capecitabine; Docetaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms XeNA
- 10 Jun 2017 Biomarkers information updated
- 01 Sep 2009 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
- 21 Aug 2009 Status changed from active, no longer recruiting to completed as reported by Roche.